Quisinostat after treatment for high-risk uveal melanoma
Part of Cancer, Eyes & vision clinical trials.
This trial tests whether taking quisinostat pills after standard treatment can lower the chance of uveal melanoma coming back in people whose original tumor had high-risk features. It is for patients who have finished their eye treatment (surgery or radiation) within the past 6 months and have no signs that the cancer has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with uveal melanoma (a type of eye cancer) and the original tumor was at least 12 millimeters wide.
- You finished your main eye treatment (surgery or radiation) within the last 6 months.
- Your tumor was classified as high-risk (class 2) by a special gene test.
- You have no evidence that the cancer has spread to other parts of your body.
- You are 18 years old or older, and your general health (ECOG score) is 0 or 1.
- You can swallow pills and do not have major stomach or bowel issues that affect absorption.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two oral medications (darovasertib and crizotinib) after standard local treatment for high-risk uveal melanoma that has not spread. The goal is to see if this treatment can reduce the risk of the cancer coming back.
This trial tests a new drug (RBP-01) given before standard treatment for uveal melanoma, a type of eye cancer. The goal is to see if the drug can shrink the tumor or improve outcomes for people who need eye removal or high-risk radiation therapy.
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
This Phase 3 study tests whether taking melatonin after treatment for uveal melanoma can reduce the chance that the cancer returns or spreads to other parts of the body. It is aimed at people with higher-risk eye melanoma features.
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
This trial tests a drug called darovasertib given before standard surgery for primary uveal melanoma (a type of eye cancer that hasn't spread). The goal is to see if the drug can shrink the tumor and improve outcomes.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.